Literature DB >> 1474259

Measurement of antigen-dependent interleukin-4 production by human peripheral blood mononuclear cells. Introduction of an amplification step using ionomycin and phorbol myristate acetate.

J A Kurtzhals1, M B Hansen, A S Hey, L K Poulsen.   

Abstract

The study of T cell responses in parasitic disease and allergy in humans has been limited by difficulties in the measurement of interleukin-4 (IL-4) in supernatants from antigen-stimulated peripheral blood mononuclear cells (PBMC). To obtain measurable amounts of IL-4 in vitro, we have added an amplification step to the antigen-specific response. Human PBMC were stimulated by tetanus toxoid (TT) or tuberculin (PPD) for 6 days and then pulsed with ionomycin and phorbol myristate acetate (PMA) for 24 h. TT-stimulated cells from nine revaccinated donors but not from seven unvaccinated donors and four that had only received childhood vaccinations against tetanus produced high levels of IL-4 (median (range) 1500 (300-3800), 316 (0-1600), and 270 (100-410) pg/ml, respectively, as measured by an enzyme linked immunosorbent assay, P = 0.005). PPD did not increase IL-4 production above the background level, although the majority of PPD-stimulated PBMC proliferated and produced interferon-gamma (IFN-gamma) in cultures without ionomycin and PMA. TT-induced IL-4 production correlated positively with proliferation. Culture supernatants did not interfere with IL-4 immunoreactivity and failed to affect ionomycin and PMA induced IL-4 production. The findings suggest that proliferating antigen-specific T cells were the source of IL-4 in these experiments. The method should prove useful for comparing the IL-4 producing ability of antigen-specific T cells from different individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1474259     DOI: 10.1016/0022-1759(92)90031-n

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Antigen-induced IL-17 response in the peripheral blood mononuclear cells (PBMC) of healthy controls.

Authors:  A Lenarczyk; J Helsloot; K Farmer; L Peters; A Sturgess; B Kirkham
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC).

Authors:  S Gasim; A M Elhassan; A Kharazmi; E A Khalil; A Ismail; T G Theander
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

3.  Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

Authors:  J A Kurtzhals; A S Hey; A Jardim; M Kemp; K U Schaefer; E O Odera; C B Christensen; J I Githure; R W Olafson; T G Theander
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

4.  Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis.

Authors:  M Kemp; A S Hey; J A Kurtzhals; C B Christensen; A Gaafar; M D Mustafa; A A Kordofani; A Ismail; A Kharazmi; T G Theander
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

5.  IL-4 mRNA expression by peritoneal cells during episodes of peritonitis in patients on continuous ambulatory peritoneal dialysis.

Authors:  C J Watson; J J Finlay-Jones; P J McDonald; P H Hart
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

6.  Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections.

Authors:  A Gaafar; A Kharazmi; A Ismail; M Kemp; A Hey; C B Christensen; M Dafalla; A Y el Kadaro; A M el Hassan; T G Theander
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.